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azathioprine therapy in Crohn's diseaseDear Sir,igure 1 Endoscopic image of the sole showing multiple light-
rown to black coloured moles.Long term use of thiopurines in the treatment of inflam-
matory bowel disease (IBD) is associated with the develop-
ment of non-melanoma skin cancer. Here we present a
patient who developed unusual skin abnormalities during
azathioprine administration.
A 22-year-old woman with known Crohn's disease (located
at her ileum en colon) since 2003 was presented at our out-
patient endoscopy unit for a routine surveillance colonosco-
py. She had been treated with maintenance therapy
azathioprine (100 mg per day) for the last 7 consecutive
years and had been in clinical remission ever since. During
endoscopy, we accidentally noticed multiple, light-brown
to black pigmented, smooth-surfaced moles of about 2 mm
in diameter on both soles (Fig. 1). Further anamnestic
assessment revealed that these moles had developed after
initiation of immunosuppressive therapy with azathioprine,
and that the moles gradually increased in number, but not
in size. After dermatological assessment, the diagnosis of
eruptive melanocytic naevi secondary to the use of azathio-
prine was established. Because of the typical aspect of the
lesions and the absence of any signs of malignant transfor-
mation, no biopsy specimens were obtained.
Eruptive melanocytic naevi, which typically develop on
hand palms and soles, are a relatively unknown adverse
effect of (longstanding) immunosuppressive therapy. The
nature of these naevi remains unclear, but regular screening
for dysplastic naevi or melanoma seems indicated, keeping
in mind the potential risk of malignant transformation.1
Whether or not surveillance colonoscopy in patients with
inflammatory bowel disease should include inspection of the
soles remains unclear.
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